Angiotensin-Converting Enzyme Inhibitor and/or Angiotensin Receptor Antagonist for the Postmyocardial Infarction Patient

Cardiology Clinics

Volumn 26, Issue 1, 2008, Pages 73-77

  Scott, Robert L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL; VALSARTAN; ZOFENOPRIL;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; COUGHING; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG USE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; STANDARD; SURVIVAL RATE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; MYOCARDIAL INFARCTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 39749158453     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.10.004     Document Type: Review

References (21)

1. Mann D. Inflammatory mediators and the failing heart: past, present and the foreseeable future. Circ Res 91 (2002) 988-998
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 23 (1987) 1429-1435
3. Domanski M., Exner D., Borkowf C., et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 33 3 (1999) 598-604
4. Pfeffer M., Braumwald E., Moye L., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 10 (1992) 669-677
5. Swedberg K., Held P., Kjekshus J., et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327 23 (1992) 678-684
6. Kober L., Torp-Petersen C., Carlsen J., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction TRACE Study Group. N Engl J Med 333 25 (1995) 1670-1676
7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
8. Borghi C., Ambrosioni E., and Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patient with preserved left ventricular function: the Survival of Myocardial Infarction Long-Term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 153 3 (2007) 445.e7-445.e14
9. The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
10. Dicpinigaitis P. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest supplement 129 (2006) 169-173
11. Barnett A., Bain S., Bouter P., et al., Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351 (2004) 1952-1961
12. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 23 (2002) 2981-2997
13. Jorde U. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact. Cardiol Rev 14 (2006) 81-87
14. Pitt B., Poole-Wilson P., Segal R., et al., ELITE II Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (2000) 1582-1587
15. Cohn J., Tognoni G., Bourge R., et al., Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 245 23 (2001) 1667-1675
16. McMurray J., Ostergren J., Svedberg K., et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 362 (2003) 767-771
17. Pfeffer M., McMurray J., Velazquez E., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 20 (2003) 1893-1906
18. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 5 (1991) 293-302
19. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 10 (1992) 685-691
20. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. The Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 10 (1999) 709-717
21. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 3 (2000) 145-153